MicroRNA-3651 Facilitates Glioma Progression by Targeting SCN3B and Serves as a Prognostic Indicator

Aim

This study is aimed at ascertaining the expression, clinical implications, and cellular functions of miR-3651 in glioma, as well as its potential target gene, Sodium Voltage-Gated Channel Beta Subunit 3 (SCN3B).

Methods

The expression of serum miR-3651 was determined in glioma using qRT-PCR. The relationship between miR-3651 expression and clinicopathological factors was assessed. Additionally, its prognostic value was evaluated using Cox regression analysis. The effects of miR-3651 on cellular processes were investigated, and its direct interaction with SCN3B was confirmed through a dual-luciferase reporter assay.

Results

Patients with glioma exhibited significantly elevated serum levels of miR-3651, which were strongly correlated with higher WHO grades, decreased KPS scores, and poorer prognoses (p < 0.001). It was established that miR-3651 serves as an independent predictor of clinical outcomes in glioma (HR = 5.387, p < 0.001). Inhibition of miR-3651 expression significantly reduced the proliferation, migration, and invasion of glioma cells while promoting apoptosis. The direct targeting of SCN3B by miR-3651 was confirmed, revealing that SCN3B expression was downregulated in glioma. Rescue experiments indicated that the overexpression of SCN3B counteracted the antitumor effects of the miR-3651 inhibitor.

Conclusion

miR-3651 is a potential prognostic marker for gliomas by targeting SCN3B to promote tumor progression. However, these findings are based on serum samples and require further validation in independent cohorts.